CA2332021A1 - Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique - Google Patents

Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique Download PDF

Info

Publication number
CA2332021A1
CA2332021A1 CA002332021A CA2332021A CA2332021A1 CA 2332021 A1 CA2332021 A1 CA 2332021A1 CA 002332021 A CA002332021 A CA 002332021A CA 2332021 A CA2332021 A CA 2332021A CA 2332021 A1 CA2332021 A1 CA 2332021A1
Authority
CA
Canada
Prior art keywords
metabolites
subject
sample
aed
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002332021A
Other languages
English (en)
Inventor
Eugene Pressman
Aaron Rabinkov
Svetlana Dolina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Neuroprotective Systems Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332021A1 publication Critical patent/CA2332021A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé et un système de diagnostic pour la détection d'une prédisposition à l'épilepsie chez un patient, pour le diagnostic de l'épilepsie clinique et pour la surveillance d'un traitement anti-épileptique. Ledit procédé consiste à prélever un échantillon sur un patient, de préférence un échantillon sanguin, à déterminer la concentration dans l'échantillon d'au moins deux métabolites de kynurénine, choisis dans le groupe constitué de TRP, L-KYN, KA, 3HOAA, AA et QUIN, ces derniers possédant des propriétés fonctionnellement opposées, et à comparer la concentration desdits métabolites dans l'échantillon et le rapport entre eux, à une plage de valeurs de ces concentrations et aux rapports entre lesdits métabolites, chez des sujets normaux. De plus, le niveau d'activité des enzymes dans les tissus périphériques, tels que les cellules sanguines, peut également être utilisé pour le diagnostic de troubles épileptiques chez un sujet et pour la détection d'une prédisposition auxdits troubles épileptiques chez ce dernier. Pour la surveillance de traitement épileptique, la plage de valeurs de deux des métabolites et le rapport entre eux sont comparés aux plages de valeurs de concentrations et au rapport entre lesdits métabolites, chez des patients épileptiques bien traités ou non par des médicaments anti-épileptiques.
CA002332021A 1998-05-12 1999-05-12 Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique Abandoned CA2332021A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12444498A IL124444A0 (en) 1998-05-12 1998-05-12 Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
IL124444 1998-05-12
PCT/IL1999/000252 WO1999058968A1 (fr) 1998-05-12 1999-05-12 Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique

Publications (1)

Publication Number Publication Date
CA2332021A1 true CA2332021A1 (fr) 1999-11-18

Family

ID=11071485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002332021A Abandoned CA2332021A1 (fr) 1998-05-12 1999-05-12 Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique

Country Status (6)

Country Link
EP (1) EP1093580A4 (fr)
JP (1) JP2002538412A (fr)
AU (1) AU3727799A (fr)
CA (1) CA2332021A1 (fr)
IL (1) IL124444A0 (fr)
WO (1) WO1999058968A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032894A2 (fr) * 2001-10-12 2003-04-24 Pfizer Products Inc. Methode de traitement neuroprotecteur de controle
AT9843U1 (de) 2007-03-27 2008-04-15 Kepplinger Berthold Dr Messung von biologischen markern
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
AU2013394569A1 (en) * 2013-07-18 2016-02-18 Dianti Ms Pty Limited Method and prognostic kit for monitoring multiple sclerosis (MS)
CN111886501A (zh) * 2018-03-19 2020-11-03 富士胶片和光纯药株式会社 精神疾病的判断方法
JP2021525865A (ja) * 2018-05-29 2021-09-27 エボゲン，インコーポレーテッド 非てんかん性発作／発作なし／心因性非てんかん性発作に対するてんかん性発作の評価および処置のためのバイオマーカーおよび方法

Also Published As

Publication number Publication date
EP1093580A1 (fr) 2001-04-25
AU3727799A (en) 1999-11-29
EP1093580A4 (fr) 2001-09-12
IL124444A0 (en) 1998-12-06
WO1999058968A1 (fr) 1999-11-18
JP2002538412A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
US7153692B2 (en) Diagnostic methods for determining susceptibility to convulsive conditions
US10551372B2 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
CA2230372C (fr) Quantification de p97 pour diagnostiquer et surveiller la maladie d'alzheimer
Giacobini The cholinergic system in Alzheimer disease
JP4838140B2 (ja) 発作性脳発射を評価するための免疫吸着血液検査
Mondello et al. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure
EP3115785A2 (fr) Procédé pour diagnostiquer ou traiter des lésions cérébrales
Youn et al. Urine neural thread protein measurements in Alzheimer disease
RU2435165C2 (ru) Биомаркеры ишемии и их применение для прогнозирования неблагоприятных неврологических последствий хирургической операции
Tang et al. Metabolomic profiling of aqueous humor and plasma in primary open angle glaucoma patients points towards novel diagnostic and therapeutic strategy
Möslinger et al. Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria
Peuchant et al. Infrared spectroscopy: a reagent-free method to distinguish Alzheimer's disease patients from normal-aging subjects
CA2332021A1 (fr) Diagnostic de la predisposition a l'epilepsie et surveillance de traitement anti-epileptique
EP1527196A2 (fr) Traitement de l'asthme ou des allergies
US8084225B2 (en) Methods for diagnosing cerebrovascular events based on NR2 peptides
Yamamoto et al. Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms
Milh et al. Genetics of neonatal onset epilepsies: an overview
CN108139389B (zh) 用于检测对象中存在与atp耗竭相关的状况的方法和装置
JP6660291B2 (ja) ニーマン・ピック病の診断のための方法
Izumi et al. Low levels of CSF gangliotetraose-series gangliosides in West syndrome: implication of brain maturation disturbance
US7879568B2 (en) Method for the diagnosis and prognosis of demyelinating diseases
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
Abd El-Aziz et al. Antinuclear antibodies and glutamic acid decarboxylase antibodies in children with refractory epilepsy
Kazakova et al. YKL-40 and Cellular Metabolic Profile in Parkinson’s Disease
Wright Autoimmunity in idiopathic epilepsies and encephalopathies of childhood

Legal Events

Date Code Title Description
FZDE Discontinued